Hemington Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hemington Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$118K	Sell	302 -7	-2%	-$2.92K	0.02%	212
2025 Q2	$137K	Sell	309 -7	-2%	-$3.23K	0.02%	185
2025 Q1	$153K	Buy	316 +23	+8%	+$10.7K	0.02%	155
2024 Q4	$117K	Buy	293 +6	+2%	+$2.78K	0.03%	173
2024 Q3	$136K	Buy	+287	New	+$138K	0.04%	153

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hemington Wealth Management's VRTX Position: Q3 2025 in Review

Hemington Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q3 2025, selling an estimated $2.92K and leaving 302 shares worth $118K. The position accounts for 0.02% of the portfolio, ranked #212.

Hemington Wealth Management first reported a position in VRTX in Q3 2024 and has held it in 5 quarters since. The position peaked at $153K in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Hemington Wealth Management held 302 shares of Vertex Pharmaceuticals worth $118K as of Q3 2025.
Hemington Wealth Management sold 7 Vertex Pharmaceuticals shares in Q3 2025, an estimated $2.92K.
Vertex Pharmaceuticals made up 0.02% of Hemington Wealth Management's portfolio in Q3 2025, its #212 holding.
Hemington Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
Hemington Wealth Management's Vertex Pharmaceuticals position peaked at $153K in Q1 2025.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.